CL2A-SN-38

  • CAT Number: I018024
  • CAS Number: 1279680-68-0
  • Molecular Formula: C₇₃H₉₇N₁₁O₂₂
  • Molecular Weight: 1480.61
  • Purity: ≥95%
Inquiry Now

CL2A-SN-38(CAT: I018024) is a conjugate of the cytotoxic drug SN-38 and a chemical linker called 3-(2-chloroethyl)-2,3-dimethylmaleic anhydride (CL2A). SN-38 is an active metabolite of the chemotherapy drug irinotecan, which is used to treat a variety of cancers, including colon, lung, and ovarian cancer. However, SN-38 has poor solubility and a narrow therapeutic index, which limits its clinical use. By conjugating SN-38 to CL2A, CL2A-SN-38 is created, which can target and bind to tumor cells, leading to the selective release of SN-38 in the tumor microenvironment. This increases the therapeutic efficacy of SN-38 while reducing the risk of systemic toxicity. CL2A-SN-38 has shown promising results in preclinical studies and is currently being evaluated in clinical trials as a potential treatment for various types of cancer.

Catalog Number I018024
CAS Number 1279680-68-0
Molecular Formula

C₇₃H₉₇N₁₁O₂₂

Purity 95%
Reference

[1]. Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69.

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!